OTCMKTS:SKYE Skye Bioscience (SKYE) Stock Forecast, Price & News $4.09 +0.63 (+18.21%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$3.90▼$4.0950-Day Range$0.01▼$3.5552-Week Range$2.11▼$10.00Volume4,288 shsAverage Volume2.53 million shsMarket Capitalization$3.97 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest About Skye Bioscience (OTCMKTS:SKYE) StockSkye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More SKYE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SKYE Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comSkye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a TrialSeptember 5, 2023 | finance.yahoo.comSkye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 30, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! August 14, 2023 | finance.yahoo.comSkye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceJuly 13, 2023 | finance.yahoo.comSkye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic EmulsionJuly 6, 2023 | msn.comSkye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical TrialJune 9, 2023 | travel.usnews.comIsle of SkyeJune 5, 2023 | finance.yahoo.comSkye Bioscience to Present at LD Micro Invitational XIIISeptember 30, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! May 15, 2023 | finance.yahoo.comSkye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic EmulsionApril 29, 2023 | finance.yahoo.comSkye Bioscience, Inc. (SKYE) Stock Historical Prices & Data - Yahoo FinanceApril 27, 2023 | finance.yahoo.comSkye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R AgonistApril 19, 2023 | msn.comShort Volatility Alert: Skye BioscienceApril 4, 2023 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic EmulsionApril 4, 2023 | finance.yahoo.comSkye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic EmulsionApril 3, 2023 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific JournalMarch 15, 2023 | msn.comEthics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of GlaucomaMarch 11, 2023 | benzinga.comSkye Bioscience Stock (OTC:SKYE), Analyst Ratings, Price Targets, PredictionsMarch 7, 2023 | finance.yahoo.comSkye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic EmulsionFebruary 24, 2023 | benzinga.comSkye Receives Positive Safety Review Of Cannabinoid Based Drug For Treatment Of Glaucoma After Second Cohort Of Phase 1 StudyFebruary 23, 2023 | proactiveinvestors.comSkye Bioscience moving ahead with SBI-100 clinical trial after positive safety reviewFebruary 16, 2023 | finance.yahoo.comSkye Bioscience Appoints Deborah Charych, PhD to Board of DirectorsFebruary 13, 2023 | finance.yahoo.comSkye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic EmulsionFebruary 2, 2023 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic EmulsionFebruary 2, 2023 | finance.yahoo.comSkye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic EmulsionJanuary 31, 2023 | proactiveinvestors.comSkye Bioscience gets positive safety review of SBI-100 OE after phase 1 first cohortJanuary 27, 2023 | msn.comSkye One Step Closer To Phase 2 Clinical Trial For Cannabinoid Based Drug For Treatment Of GlaucomaSee More Headlines Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address SKYE Company Calendar Today9/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone(858) 410-0266FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,480,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-453.10% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-409.00Miscellaneous Outstanding Shares971,550,000Free Float956,005,000Market Cap$3.97 billion OptionableNot Optionable Beta0.62 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Punit S. Dhillon B.A. (Age 43)BA, Exec. Chairman, Pres, CEO & Sec. Comp: $733.08kMs. Kaitlyn Melanie Arsenault CPA (Age 36)Chief Financial Officer Comp: $455.89kDr. Christopher G. Twitty Ph.D. (Age 50)Chief Scientific Officer Mr. Tu Diep M.Sc.Chief Devel. OfficerKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXFortreaNASDAQ:FTREArcellxNASDAQ:ACLXAxsome TherapeuticsNASDAQ:AXSMEvotecNASDAQ:EVOView All Competitors SKYE Stock - Frequently Asked Questions How have SKYE shares performed in 2023? Skye Bioscience's stock was trading at $0.0162 at the beginning of 2023. Since then, SKYE shares have increased by 25,146.9% and is now trading at $4.09. View the best growth stocks for 2023 here. Are investors shorting Skye Bioscience? Skye Bioscience saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 24,200 shares, a decline of 67.2% from the August 15th total of 73,800 shares. Based on an average daily volume of 6,559,700 shares, the short-interest ratio is presently 0.0 days. View Skye Bioscience's Short Interest. What is Skye Bioscience's stock symbol? Skye Bioscience trades on the OTCMKTS under the ticker symbol "SKYE." How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Skye Bioscience's stock price today? One share of SKYE stock can currently be purchased for approximately $4.09. How much money does Skye Bioscience make? Skye Bioscience (OTCMKTS:SKYE) has a market capitalization of $3.97 billion. The company earns $-19,480,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. How can I contact Skye Bioscience? Skye Bioscience's mailing address is 5910 PACIFIC CENTER BLVD SUITE 320, SAN DIEGO CA, 92121. The official website for the company is skyebioscience.com. The company can be reached via phone at (858) 410-0266 or via email at invest@emeraldbio.life. This page (OTCMKTS:SKYE) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.